Aviva Bio's AVA-291 therapy targets FDA safety concerns for women's testosterone

Aviva Bio's investigational drug AVA-291 is designed to address FDA-identified safety concerns for testosterone therapy in women, specifically regarding breast cancer risk. The company is preparing for first-in-human studies.